187
Participants
Start Date
January 3, 2018
Primary Completion Date
April 5, 2024
Study Completion Date
May 31, 2025
Escitalopram
5-15 mg/day (target: 15mg/day if tolerated)
Placebo
Masked placebo
Columbia University, New York
University of Rochester Medical Center, Rochester
Alzheimer Disease Research Center; University of Pittsburgh, Pittsburgh
Abington Neurological Associates, Ltd, Abington
Maryland VA Health Care System, Baltimore
Johns Hopkins University School of Medicine, Bayview Medical Center, Baltimore
University of Virginia Adult Neurology, Charlottesville
Eastern Virginia Medical School, Norfolk
Roper St. Francis Healthcare, Charleston
Miami Jewish Health Systems, Miami
Ohio State University, Columbus
Kansas School of Medicine-Wichita Center for Clinical Research, Wichita
Biomedical Research Foundation, Little Rock
University of Arkansas for Medical Sciences, Little Rock
Baylor AT&T Memory Center, Dallas
UT Health San Antonio, San Antonio
Banner Sun Health Research Institute, Sun City
University of California Los Angeles/VA Greater Los Angeles Healthcare System, Los Angeles
University of Southern California Keck School of Medicine Memory and Aging Center, Los Angeles
Northwest Clinical Research Center, Bellevue
Alzheimer Disease Center, Quincy
Hackensack Meridian Health, Hackensack
University of Calgary and Foothills Medical Centre, Calgary
Centre for Memory and Aging, Toronto
Lawson Health Research Institute/Parkwood Institute, London
Neuropsychopharmacology Research Group, Sunnybrook, Toronto
Unity Health, Toronto
Centre for Addiction and Mental Health, Toronto
Ontario Shores, Whitby
Lead Sponsor
National Institute on Aging (NIA)
NIH
JHSPH Center for Clinical Trials
OTHER